Patents by Inventor Guo-Qiang Cao
Guo-Qiang Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8349868Abstract: Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.Type: GrantFiled: May 17, 2011Date of Patent: January 8, 2013Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Roland Burli, Marian C. Bryan, Guo-Qiang Cao, Susana C. Neira, Anthony B. Reed
-
Patent number: 8048892Abstract: are useful as inhibitors of HIF prolyl hydroxylases where the definitions of the variables are provided herein.Type: GrantFiled: December 17, 2007Date of Patent: November 1, 2011Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Kaustav Biswas, Guo-Qiang Cao, Jennifer E. Golden, Stephanie Mercede, Tanya Peterkin, Anthony Reed, Christopher M. Tegley
-
Patent number: 8048894Abstract: Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.Type: GrantFiled: April 16, 2008Date of Patent: November 1, 2011Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Roland Burli, Marian C. Bryan, Guo-Qiang Cao, Susana C. Neira, Anthony B. Reed
-
Publication number: 20110224248Abstract: Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.Type: ApplicationFiled: May 17, 2011Publication date: September 15, 2011Applicant: Amgen Inc.Inventors: Jennifer R. Allen, Roland Burli, Marian C. Bryan, Guo-Qiang Cao, Susana C. Neira, Anthony B. Reed
-
Patent number: 7928139Abstract: Compounds of Formula I and Formula II are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.Type: GrantFiled: November 4, 2009Date of Patent: April 19, 2011Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Kaustav Biswas, Marian C. Bryan, Roland Burli, Guo-Qiang Cao, Michael J. Frohn, Jennifer E. Golden, Stephanie Mercede, Susana Neira, Tanya Peterkin, Alexander J. Pickrell, Anthony Reed, Christopher M. Tegley, Xiang Wang
-
Patent number: 7759337Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein B, R1, R2, R3, R4 and R5 are d.efined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: GrantFiled: March 2, 2006Date of Patent: July 20, 2010Assignee: Amgen Inc.Inventors: Andrew Tasker, Dawei Zhang, Guo-Qiang Cao, Partha Pratim Chakrabarti, James Richard Falsey, Bradley J. Herberich, Randall W. Hungate, Liping H. Pettus, Anthony Reed, Robert M. Rzasa, Kelvin K. C. Sham, Maya C. Thaman, Shimin Xu
-
Publication number: 20100048572Abstract: Compounds of Formula I and Formula II are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.Type: ApplicationFiled: November 4, 2009Publication date: February 25, 2010Applicant: Amgen Inc.Inventors: Jennifer R. Allen, Kaustav Biswas, Marian C. Bryan, Roland Burli, Guo-Qiang Cao, Michael J. Frohn, Jennifer E. Golden, Stephanie Mercede, Susana Neira, Tanya Peterkin, Alexander J. Pickrell, Anthony Reed, Christopher M. Tegley, Xiang Wang
-
Patent number: 7635715Abstract: Compounds of Formula I and Formula II are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.Type: GrantFiled: December 17, 2007Date of Patent: December 22, 2009Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Kaustav Biswas, Marian C. Bryan, Roland Burli, Guo-Qiang Cao, Michael J. Frohn, Jennifer E. Golden, Stephanie Mercede, Susana Neira, Tanya Peterkin, Alexander J. Pickrell, Anthony Reed, Christopher M. Tegley, Xiang Wang
-
Publication number: 20090156605Abstract: Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.Type: ApplicationFiled: April 16, 2008Publication date: June 18, 2009Applicant: Amgen Inc.Inventors: Jennifer R. Allen, Roland Burli, Marian C. Bryan, Guo-Qiang Cao, Susana C. Neira, Anthony B. Reed
-
Publication number: 20090149468Abstract: The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs.Type: ApplicationFiled: February 4, 2009Publication date: June 11, 2009Applicant: Amgen Inc.Inventors: Guo-Qiang Cao, Jian J. Chen, Celia Dominguez, Anthony Reed, Kelvin K.C. Sham, Maya C. Thaman, Dawei Zhang, Bradley J. Herberich
-
Publication number: 20090111806Abstract: are useful as inhibitors of HIF prolyl hydroxylases where the definitions of the variables are provided herein.Type: ApplicationFiled: December 17, 2007Publication date: April 30, 2009Applicant: Amgen Inc.Inventors: Jennifer R. Allen, Kaustav Biswas, Guo-Qiang Cao, Jennifer E. Golden, Stephanie Mercede, Tanya Peterkin, Anthony Reed, Christopher M. Tegley
-
Publication number: 20090093483Abstract: Compounds of Formula I and Formula II are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.Type: ApplicationFiled: December 17, 2007Publication date: April 9, 2009Applicant: Amgen Inc.Inventors: Jennifer R. Allen, Kaustav Biswas, Marian C. Bryan, Roland Burli, Guo-Qiang Cao, Michael J. Frohn, Jennifer E. Golden, Stephanie Mercede, Susana Neira, Tanya Peterkin, Alexander J. Pickrell, Anthony Reed, Christopher M. Tegley, Xiang Wang
-
Patent number: 7410998Abstract: Benzopyran-based inhibitors of NADH:ubiquinone oxidoreductase for inhibiting the growth of cancer cells.Type: GrantFiled: September 6, 2001Date of Patent: August 12, 2008Assignee: The Scripps Research InstituteInventors: Kyriacos C. Nicolaou, Jeffrey Pfefferkorn, Guo-Qiang Cao, Anthony Roecker
-
Publication number: 20070054916Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.Type: ApplicationFiled: September 30, 2005Publication date: March 8, 2007Inventors: Vinod Patel, Joseph Kim, Stephanie Geuns-Meyer, Stuart Chaffee, Victor Cee, Brian Hodous, Steven Bellon, Jean-Christophe Harmange, Philip Olivieri, Maya Thaman, Erin DiMauro, John Buchanan, David McGowan, Brian Albrecht, Holly Deak, Jean Bemis, Ryan White, Matthew Martin, Gregory Habgood, Paul Tempest, Craig Masse, William Buckner, Bradley Herberich, Russell Graceffa, Dawei Zhang, Shimin Xu, Kelvin Sham, Robert Rzasa, James Falsey, Partha Chakrabarti, Guo-Qiang Cao, Susan Tomlinson, Liping Pettus, Adrian Smith, Nick Paras, Gang Liu, Frenel DeMorin, Andrew Tasker, Anthony Reed
-
Publication number: 20060199817Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: ApplicationFiled: March 2, 2006Publication date: September 7, 2006Applicant: Amgen Inc.Inventors: Andrew Tasker, Dawei Zhang, Guo-Qiang Cao, Partha Chakrabarti, James Falsey, Bradley Herberich, Randall Hungate, Liping Pettus, Anthony Reed, Robert Rzasa, Kelvin Sham, Maya Thaman, Shimin Xu
-
Patent number: 7026326Abstract: The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs.Type: GrantFiled: May 13, 2003Date of Patent: April 11, 2006Assignee: Amgen Inc.Inventors: Guo-Qiang Cao, Celia Dominguez, Martin H. Goldberg, Fang-Tsao Hong, Kelvin K. C. Sham, Seifu Tadesse, Nuria A. Tamayo, Kurt E. Weiler, Dawei Zhang, Hongyu Liao
-
Patent number: 6967254Abstract: The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs.Type: GrantFiled: September 8, 2003Date of Patent: November 22, 2005Assignee: Amgen Inc.Inventors: Celia Dominguez, Dawei Zhang, Kelvin K. C. Sham, Guo-Qiang Cao
-
Publication number: 20050182072Abstract: The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs.Type: ApplicationFiled: January 11, 2005Publication date: August 18, 2005Inventors: Guo-Qiang Cao, Jian Chen, Celia Dominguez, Anthony Reed, Kelvin Sham, Maya Thaman, Dawei Zhang, Bradley Herberich
-
Publication number: 20050038010Abstract: The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs.Type: ApplicationFiled: May 13, 2003Publication date: February 17, 2005Inventors: Guo-Qiang Cao, Celia Dominguez, Martin Goldberg, Fang-Tsao Hong, Kelvin Sham, Seifu Tadesse, Nuria Tamayo, Kurt Weiler, Dawei Zhang, Hongyu Liao
-
Publication number: 20040034239Abstract: Novel benzopyran-based inhibitors of NADH:ubiquinone oxidoreductase are designed, synthesized, and shown to have anti-cancer activity.Type: ApplicationFiled: July 23, 2003Publication date: February 19, 2004Inventors: Kyriacos C Nicolaou, Jeffrey Pfefferkorn, Guo-Qiang Cao, Anthony Roecker